Holdings
Birchview Capital, LP
As of Jun 30, 2026, Birchview Capital, LP reported 58 positions worth US$189M. Largest: Kla Corporation, Bristol-myers Squibb Company and Lam Research Corporation. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Kla Corporation | 178K | US$53.8M | +159K | Jun 30, 2026 |
| Bristol-myers Squibb Company | 297K | US$17.1M | −9,025 | Jun 30, 2026 |
| Lam Research Corporation | 35,000 | US$15.2M | −1,000 | Jun 30, 2026 |
| Intellia Therapeutics, Inc. | 386K | US$6.78M | −59,500 | Jun 30, 2026 |
| Solid Biosciences Inc. | 666K | US$6.66M | +40,216 | Jun 30, 2026 |
| Stoke Therapeutics, Inc. | 178K | US$5.83M | −31,890 | Jun 30, 2026 |
| Ovintiv Inc. (de) | 108K | US$5.66M | no change | Jun 30, 2026 |
| Nektar Therapeutics | 81,000 | US$5.65M | +50,000 | Jun 30, 2026 |
| Corcept Therapeutics Incorporated | 57,200 | US$4.97M | +10,000 | Jun 30, 2026 |
| Neurocrine Biosciences, Inc. | 27,190 | US$4.58M | no change | Jun 30, 2026 |